Efficacy, Safety, Tolerability, and Pharmacokinetics of Human Immune Globulin Subcutaneous, 20% (IGSC 20%): Final Analysis of a Phase 2/3 Study in Patients with Primary Immunodeficiency Disease (PIDD) in North America

Efficacy, Safety, Tolerability, and Pharmacokinetics of Human Immune Globulin Subcutaneous, 20% (IGSC 20%): Final Analysis of a Phase 2/3 Study in Patients with Primary Immunodeficiency Disease (PIDD) in North America

Results Seventy-four patients aged 3-83 years received IGSC 20% and 67 completed; no patient discontinued IGSC 20% due to a serious adverse event (SAE) or adverse reaction (AR).

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of allergy and clinical immunology 2016-02, Vol.137 (2), p.AB221-AB221
Hauptverfasser: Suez, Daniel, MD, FAAAAI, Melamed, Isaac, MD, Hussain, Iftikhar, MD, FAAAAI, Stein, Mark R., MD, FAAAAI, Gupta, Sudhir, MD, PhD, FAAAAI, Paris, Kenneth, MD, MPH, Fritsch, Sandor, PhD, Bourgeois, Christelle, PhD, Leibl, Heinz, PhD, McCoy, Barbara, PhD, Yel, Leman, MD, FAAAAI
Format: Artikel
Sprache:eng
Schlagworte:
Allergy and Immunology
Infections
Prescription drugs
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Results Seventy-four patients aged 3-83 years received IGSC 20% and 67 completed; no patient discontinued IGSC 20% due to a serious adverse event (SAE) or adverse reaction (AR).
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2015.12.856